By continuing to use our site, you consent to the processing of cookies, user data (location information, type and version of the OS, the type and version of the browser, the type of device and the resolution of its screen, the source of where the user came from, from which site or for what advertisement, language OS and Browser, which pages are opened and to which buttons the user presses, ip-address) for the purpose of site functioning, retargeting and statistical surveys and reviews. If you do not want your data to be processed, please leave the site.

The Voice of People With Breast Cancer

FIND THE BREAST CANCER DRUG INFORMATION YOU NEED
MedSearch

Generic Name

Ribociclib (with Aromatase Inhibitor)

Brand Name

Kisqali
Novartis

Product Monograph

Stage IV (metastatic)
HR+
Targeted therapy
Oral drug
Listed on Provincial/Territorial drug Formulary

The process of getting a drug approved and publicly funded in Canada is complex and lengthy. CBCN has created an infographic on how drugs get funded in Canada to make understanding Canada’s drug approval process a little easier. Access the infographic here.

Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Northwest Territories, Nunavut, Ontario, Prince Edward Island, Québec, Saskatchewan, Yukon
Yes
No

To support patients with unresectable or metastatic breast cancer who have been prescribed Kisqali, Novartis has opened a Patient Support Program (PSP) called Sentia. Patients enrolled by their healthcare team in the PSP will have access to reimbursement navigation and financial assistance, dedicated nurses to answer any questions you may have, helpful information and tools to support you, and one year of ongoing personal support.

Note that reimbursement timelines can vary on a case-by-case basis. If you have questions you can contact the PSP directly at the following:

Fax: 1-866-636-8421
Email: psp@sentia-exp.ca
Phone: 1-855-736-8421 (1-855-SENTIA-1)